Methylphenidate-Induced Raynaud’s Phenomenon In Two Cases With Attention-Deficit/Hyperactivity Disorder

Abstract

Attention-deficit/hyperactivity disorder is a common neurodevelopmental disorder in childhood, for which there are several different treatment options. Among the suggested medications, methylphenidate (a central nervous system stimulant) is the first option in the treatment of ADHD. Psychostimulants are associated with various vascular problems including peripheral vasculopathy. This report describes two patients with ADHD who developed Raynaud's phenomenon during the modified-release methylphenidate treatment.

Keywords

• methylphenidate
• Raynaud’s phenomenon
• ADHD

Dikkat Eksikliği / Hiperaktivite Bozukluğu Olan İki Olguda Metilfenidat Kaynaklı Raynaud Fenomeni

Abstract

Dikkat eksikliği / hiperaktivite bozukluğu, çocukluk çağında çok sayıda farklı tedavi seçeneği bulunan yaygın bir nörogelişimsel bozukluktur. Önerilen ilaçlar arasında metilfenidat (bir santral sinir sistemi stimülasyonu) DEHB tedavisinde ilk seçenektir. Psikostimülanlar, periferik vaskülopati dahil olmak üzere çeşitli vasküler problemlerle ilişkilidir. Bu raporda, modifiye salınımlı metilfenidat tedavisi sırasında Raynaud fenomeni geliştiren iki DEHB hastası sunulmaktadır.

Keywords

• metilfenidat
• Raynaud fenomeni
• DEHB

References

1. 1. Storebø OJ, Pedersen N, Ramstad E et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev. 2018;2018(5).
2. 2. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006;59(4):243–51.
3. 3. Jefferson HJ, Jayne DR Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant. 1999;14(7):1761–3.
4. 4. Cantu C, Arauz A, Murillo Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667–72.
5. 5. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud’s phenomenon: From molecular pathogenesis to therapy. Autoimmun Rev [Internet]. 2014;13(6):655–67.
6. 6. Jaffe I. Serotonin reuptake inhibitors in Raynaud’s phenomenon. Lancet. 1995;345(8961):1378.
7. 7. Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, Kamal M, Hamzei E. Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects. Curr Pharm Des. 2016;22(5):590–4.
8. 8. Faraone S V. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.

9. 9. Wigley FM. Raynaud’s phenomenon. N Engl J Med. 2002;347(13):1001–8.
10. 10. Peiro AM, Margarit C TM. Citalopram-induced Raynaud’s phenomenon. Rheumatol Int. 2007;27:599–601.
11. 11. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14(1):30–3.
12. 12. Bayram Ö, Hergüner S. OROS-methylphenidate-induced Raynaud’s phenomenon: A dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521–2.
13. 13. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12(2):111–5.